Predictors of drug hypersensitivity in HIV infected subjects

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12605000491662

Enrollment

Registered

2005-09-23

Start date

2005-08-03

Completion date

2008-06-30

Last updated

2021-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Drug hypersensitivity reactions mediated by T cells are increased in HIV infection and particular HLA types have been associated with reactions to the antiretroviral drugs Abacavir [HLA-B*5701] and Nevirapine [HLA-DRB1*0101]. B57 strongly predicts reactions with Abacavir probably via a direct effect of the drug on dendritic cell activation. Abacavir naïve subjects with B57 can also generate immunological response during in vitro culture suggesting a high precursor frequency for abacavir specific T cells responses. This project aims to determine how these drugs lead to hypersensitivity reactions and to define the genetic and immunological factors that can be used to predict reactions.

Interventions

A case-control study to investigate hypersensitivie and tolerant individuals matched for HLA predispositions.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Treatment with the antiretroviral drugs Efavirenz, Nevirapine, or Abacavir.

Exclusion criteria

No exclusion criteria

Outcome results